Bencycloquidium Bromide Eye Drops for Slowing Myopia Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective drugs for preventing or treating myopia, particularly in children and adolescents, with existing treatments like atropine eye drops causing adverse reactions such as photophobia and allergic conjunctivitis.
Innovation Solution
Utilizing bencycloquidium bromide, its isomers, and derivatives in the formulation of ophthalmic drugs, specifically eye drops, to prevent and treat myopia by inhibiting ocular axial length change and myopic refractive error, with formulations optimized for stability and reduced eye irritation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If atropine eye drops with low-concentrations are used to treat myopia, then the ease of operation is improved, but object-affected harmful factors worsen due to photophobia, blurred near vision, and allergic conjunctivitis
Solution Approach 1:
The patent changes the chemical substance parameter from atropine to bencycloquidium bromide, which has different pharmacological properties. This substitution maintains the therapeutic effect on myopia while reducing adverse reactions such as photophobia and allergic conjunctivitis, thus resolving the contradiction between ease of use and harmful effects
2Reliability
If there are not many drugs available clinically for myopia prevention and treatment, then the reliability is improved by limiting options to proven treatments, but productivity worsens due to lack of treatment choices
Solution Approach 1:
The patent segments the limited treatment options by introducing a new drug class (bencycloquidium bromide) that addresses specific unmet needs in myopia treatment. This creates a differentiated treatment pathway that expands productivity while maintaining reliability through targeted therapeutic mechanisms
3Object-affected harmful factors
If bencycloquidium bromide is used in ophthalmic formulation, then object-affected harmful factors are reduced by minimizing adverse reactions, but manufacturing precision worsens due to formulation optimization requirements
Solution Approach 1:
The patent optimizes formulation parameters including pH adjustment to 6.0-7.5 and addition of stabilizing agents to ensure drug stability while minimizing eye irritation. This resolves the contradiction by precisely controlling manufacturing parameters to achieve both reduced harmful effects and maintained formulation stability
Data Source
AI summary
The present invention relates to the technical field of medicine, and in particular to a use of bencycloquidium bromide, an isomer thereof and a derivative thereof in the preparation of a drug for preventing or treating an ophthalmic disease. Moreover, the present invention provides an ophthalmic formulation using the bencycloquidium bromide, the isomer thereof and the derivative thereof as active ingredients. According to the present invention, by using the bencycloquidium bromide, the isomer thereof and the derivative thereof in eyes, it is discovered that the bencycloquidium bromide, the isomer thereof and the derivative thereof have an obvious inhibitory effect on changes in ocular axial length and diopter in the progression process of a myopic refractive error, and then it is discovered that the ophthalmic formulation using the bencycloquidium bromide, the isomer thereof and the derivative thereof as active ingredients has significant advantages in the prevention and treatment of ophthalmic diseases, especially in preventing myopia and slowing down the progression of myopia, etc.